It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...

Clinical-stage biotech Recursion Pharmaceuticals ' (NASDAQ: RXRX) stock took it on the chin in the first trading day of the ...

Contribute to 7908837174/ALL-IN-ONE development by creating an account on GitHub.

Contribute to Babul422/functions-recursion development by creating an account on GitHub.